Experimental Hematology & Oncology

Scope & Guideline

Transforming Research into Breakthroughs in Hematology & Oncology

Introduction

Welcome to the Experimental Hematology & Oncology information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Experimental Hematology & Oncology, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationEXP HEMATOL ONCOL / Exp. Hematol. Oncol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

Experimental Hematology & Oncology focuses on advancing the understanding and treatment of hematological malignancies and related oncological challenges through innovative research and experimental approaches.
  1. Immunotherapy and Cellular Therapies:
    The journal prominently features research on immunotherapeutic strategies, particularly CAR-T cell therapies and their applications in various blood cancers, reflecting a commitment to explore cutting-edge cellular therapies.
  2. Molecular and Genetic Insights:
    Emphasizing the role of genetic mutations and molecular pathways in cancer progression, the journal publishes studies that delve into the molecular underpinnings of hematological malignancies and their therapeutic implications.
  3. Tumor Microenvironment and Metabolism:
    Research on the tumor microenvironment, including interactions with immune cells and metabolic reprogramming, is a core focus area, highlighting the complexity of cancer biology and potential therapeutic targets.
  4. Clinical Applications and Real-World Studies:
    The journal prioritizes studies that translate laboratory findings into clinical practice, including multicenter trials and real-world outcomes of hematopoietic stem cell transplantation and novel therapeutic regimens.
  5. Emerging Therapeutic Strategies:
    It also explores novel therapeutic agents and combinations, including small molecules, bispecific antibodies, and targeted therapies, reflecting the journal's commitment to addressing evolving treatment landscapes.
The journal is increasingly focusing on innovative and evolving themes that reflect the current landscape of hematology and oncology research, capturing the latest advancements and emerging areas of interest.
  1. Advancements in CAR-T Cell Therapy:
    There is a significant trend towards exploring various aspects of CAR-T cell therapies, including novel constructs, combination therapies, and innovative delivery mechanisms, highlighting the potential for personalized cancer treatment.
  2. Integrative Approaches to Tumor Microenvironment:
    Increasing attention is being paid to the tumor microenvironment, with studies investigating how immune cells, stromal components, and metabolic factors influence tumor progression and therapy response.
  3. Focus on Biomarkers and Precision Medicine:
    Emerging themes include the identification of biomarkers for predicting treatment response and disease progression, emphasizing the shift towards precision medicine in hematological malignancies.
  4. Role of Artificial Intelligence in Oncology:
    Recent publications have begun to explore the application of AI and machine learning in diagnostics and treatment planning, indicating a growing interest in leveraging technology to enhance clinical outcomes.
  5. Research on Novel Therapeutic Targets:
    The journal is increasingly featuring studies on new therapeutic targets and pathways, particularly those involved in immune evasion and resistance mechanisms, reflecting a proactive approach to developing next-generation therapies.

Declining or Waning

While the journal continues to thrive in many areas, certain themes appear to be declining in prominence, reflecting shifts in research priorities and advancements in the field.
  1. Traditional Chemotherapy Approaches:
    Research focusing on standard chemotherapy regimens is becoming less frequent, as newer targeted therapies and immunotherapies gain traction and demonstrate improved efficacy and safety profiles.
  2. Less Emphasis on Single-Agent Therapies:
    There is a noticeable decline in studies centered on single-agent therapies, as combination therapies and multi-targeted approaches are increasingly recognized for their potential to overcome resistance.
  3. Limited Exploration of Older Drug Classes:
    The exploration of older drug classes and their mechanisms is waning, as the focus shifts towards innovative compounds and novel mechanisms of action that promise better clinical outcomes.
  4. Decreased Interest in Basic Laboratory Models:
    Research utilizing basic laboratory models without translational implications appears to be declining, as the journal emphasizes studies that bridge laboratory findings to clinical relevance.
  5. Reduction in Studies on Rare Hematological Disorders:
    There seems to be a decrease in the volume of research dedicated to rare hematological disorders, likely due to the concentration on more prevalent and impactful malignancies.

Similar Journals

HEMATOLOGICAL ONCOLOGY

Advancing the Frontiers of Hematological Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Blood Cancer Journal

Fostering collaboration in the fight against blood cancer.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

Journal of Hematology & Oncology

Pioneering Discoveries in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Connecting Scholars in the Pursuit of Blood Knowledge
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Indian Journal of Hematology and Blood Transfusion

Elevating Knowledge: Your Source for Hematology Excellence
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

Blood Science

Fostering Excellence in Blood Science Research
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Transforming knowledge into practice in cancer care.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

LEUKEMIA & LYMPHOMA

Advancing knowledge in blood cancer research.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Enhancing understanding, improving outcomes for young patients.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1077-4114Frequency: 8 issues/year

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, published by Lippincott Williams & Wilkins, serves as a vital platform for the dissemination of cutting-edge research and insights in the fields of pediatric hematology and oncology. Since its inception in 1979, the journal has maintained a commitment to advancing knowledge through peer-reviewed articles that contribute to the understanding and treatment of blood disorders and cancers in children. With an impact factor reflective of its academic contributions, the journal is positioned in the Q3 quartile across key medical categories — Hematology, Oncology, and Pediatrics, Perinatology and Child Health — indicating its relevance and influence in the field. While it does not currently offer open access options, the journal remains a crucial resource for researchers, clinicians, and students dedicated to improving pediatric care and outcomes. Researchers are encouraged to contribute to this esteemed journal as it seeks to bridge the gap between clinical practice and research, fostering innovation and improved quality of life for young patients affected by hematologic and oncologic conditions.

Journal of Hematology

Exploring the Depths of Hematological Research
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.